Suchergebnisse - "Pietrantuono, Giuseppe"

PubPharm (6)

1

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

enthalten in: Hematological oncology | 2022

von Bruzzese, A. | Derudas, D. | Galli, M. | +57

2

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

enthalten in: Blood | 2016

von Magarotto, V. | Bringhen, S. | Offidani, M. | +23

ErratumIn: Blood. 2018 Mar 29;131(13):1495. - PMID 29599148

3

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor : results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study

enthalten in: Stem cell research & therapy | 2015

von Musto, P. | Simeon, V. | Grossi, A. | +19

4

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma : updated results

enthalten in: Blood | 2013

von Gay, F. | Magarotto, V. | Crippa, C. | +18

ErratumIn: Blood. 2014 Jun 12;123(24):3843

5

Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia

enthalten in: Leukemia research | 2008

von Musto, P. | Pietrantuono, G. | Guariglia, R. | +5

6

Role of thalidomide in previously untreated patients with multiple myeloma

enthalten in: Expert review of anticancer therapy | 2008

von Musto, P. | D'Auria, F. | Pietrantuono, G. | +9

1
[1]